Physician profile
Janet Leon
NPI 1962504613
$19,939.57
in general payments reported to CMS, 2019-2025
34 companies · $3,021 in 2025
The $3,021 reported for 2025 was more than what 77% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,808 · 2020: $1,199 · 2021: $2,619 · 2022: $3,776 · 2023: $2,389 · 2024: $3,129 · 2025: $3,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,537 · Education: $0.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,537.35 |
| Education | $0.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,429.83 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $3,013.71 | 2019-2025 | |
| Janssen Biotech, INC. | $1,999.75 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,821.96 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,591.27 | 2019-2025 | |
| Horizon Therapeutics Plc | $1,338.94 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $1,108.93 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $988.86 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $916.28 | 2020-2025 | Acthar |
| Pfizer INC. | $625.79 | 2019-2025 | |
| Lilly USA, LLC | $369.93 | 2019-2024 | Taltz |
| Regeneron Healthcare Solutions, INC. | $296.84 | 2019-2020 | |
| Sandoz INC. | $231.38 | 2023-2025 | Hyrimoz |
| Genzyme Corporation | $231.03 | 2020-2025 | |
| Celgene Corporation | $213.66 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $209.82 | 2022-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.69 | 2020-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $200.46 | 2022-2025 | Lupkynis |
| Genentech USA, INC. | $154.10 | 2019-2024 | Actemra |
| Ani Pharmaceuticals, INC. | $151.69 | 2022-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $123.26 | 2019 | |
| Pacira Therapeutics, INC. | $110.42 | 2019-2021 | |
| Sobi, INC | $107.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $104.14 | 2024 | |
| Mallinckrodt Enterprises LLC | $98.21 | 2019 | |
| Organon LLC | $82.66 | 2024-2025 | Hadlima, Renflexis |
| Antares Pharma, INC. | $65.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $36.72 | 2019-2020 | |
| Radius Health, INC. | $29.24 | 2021-2022 | |
| United Therapeutics Corporation | $26.98 | 2024 | Tyvaso |
| Kiniksa Pharmaceuticals International, Plc | $16.82 | 2024 | Arcalyst |
| Ferring Pharmaceuticals INC. | $12.74 | 2020 | |
| Hikma Pharmaceuticals USA | $11.46 | 2019 | |
| Orthogenrx INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.